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Abstract
Purpose Studies comparing CSF and PET tau biomarkers have included only commercial CSF assays examining specific
phosphorylation sites (e.g. threonine 181, P-tau181p) and mid-domain tau (i.e. total tau, T-tau). Moreover, these studies did not
examine CSF tau levels in relation to cerebral glucose metabolism. We thus aimed to examine CSF tau measures, using both
commercial and novel assays, in relation to [18F]THK5317 (tau) and [18F]FDG PET (glucose metabolism).
Methods Fourteen Alzheimer’s disease (AD) patients (seven prodromal, seven dementia) underwent [18F]THK5317 and
[18F]FDG PET studies, with follow-up performed in ten subjects (six prodromal, four dementia) after 17 months. In addition
to commercial assays, novel measures capturing N-terminus+mid-domain (tau N-Mid) and C-terminally truncated (tau-368)
fragments were included.
Results While the levels of all forms of CSF tau were found to be inversely associated with baseline [18F]FDG uptake,
associations with baseline [18F]THK5317 uptake varied in relation to the degree of isocortical hypometabolism
([18F]FDG SUVR). Changes in the levels of the novel CSF markers tracked longitudinal changes in tracer uptake better
than changes in P-tau181p and T-tau levels, and improved concordance with dichotomized regional [
18F]THK5317
measures.
Conclusion Our findings suggest that neurodegeneration may modulate the relationship between CSF and PET tau
biomarkers, and that, by comparison to P-tau181p and T-tau, tau-368 and tau N-Mid may better capture tau pathology
and synaptic impairment.
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Introduction
Although many details surrounding the pathogenesis of
Alzheimer’s disease (AD) remain unclear, a dominant viewpoint
is that the dysmetabolism of amyloid-β (Aβ) initiates tau pathol-
ogy that results in neurodegeneration and cognitive decline.
Cerebrospinal fluid (CSF) measures of tau include phosphorylat-
ed tau (P-tau), an indicator of an abnormal state associated with
the formation of neurofibrillary tangle (NFT) pathology, and total
tau (T-tau), that reflects the intensity of axonal and neuronal
damage [1]. Recently, positron emission tomography (PET) li-
gands selective for AD-related paired helical filament (PHF) tau
present in NFTs have been introduced into the field.
One such ligand is [18F]flortaucipir (formerly known as
[18F]T-807 and [18F]AV1451) [2, 3], and studies examining the
relationship between [18F]flortaucipir uptake and CSF tau levels
have shown modest positive correlations in cognitively unim-
paired older adults and in patients with AD and non-AD neuro-
degenerative disorders [4–7]. These studies, however, used com-
mercial assays that use monoclonal antibodies directed against
specific phosphorylation sites (e.g. threonine-181, P-tau181p) and
the mid-region of tau (i.e. T-tau) [8, 9]. Increasing evidence,
however, indicates the presence of tau fragments spanning both
the mid-domain and various terminal regions [10], suggesting
that assays targeting specific variants of tau may be required to
more fully characterize the relationship between CSF and PET
tau biomarkers. Moreover, these studies did not examine the link
between CSF tau levels and [18F]FDG PET, an important mea-
sure given evidence indicating that synaptic integrity mediates
the impact of tau on cognition [11].
The aims of this study were thus to investigate the associ-
ation between CSF tau levels, derived from both commercial
assays (P-tau181p and T-tau) [8, 9] and novel assays, the latter
including N-terminus plus mid-domain regions (tau N-Mid)
and C-terminally truncated tau (tau-368), and longitudinal
findings using the tau PET tracer [18F]THK5317
[(S)-[18F]THK5117] [12–14] and [18F]FDG in a sample of
patients with AD. Given findings suggesting that disease pro-
gression may be accompanied by a reduction in CSF tau [15,
16], it was hypothesized that the degree of glucose
hypometabolism may modulate associations between CSF
tau levels and [18F]THK5317 uptake. Further, in light of the
likely future clinical use of tau imaging, we also aimed to
examine the agreement between dichotomized CSF tau levels
and [18F]THK5317 uptake.
Materials and methods
Study sample
Fourteen patients with AD (seven prodromal AD, seven AD
dementia), and nine cognitively unimpaired individuals
(THK-controls; five young, 20–30 years old, four elderly,
58–71 years old) who had previously participated in baseline
investigations were included [11, 17]. Follow-up
[18F]THK5317 and [18F]FDG PET data were acquired in ten
AD patients (six prodromal, four dementia) after a median of
17 months (interquartile range, IQR, 15–18 months) [18].
Baseline cross-sectional [18F]THK5317 and [18F]FDG PET
studieswere performedwithin 1.5months (IQR1–2.7months)
and follow-up studies within 0.5 months (IQR 0–1 months).
CSF samples were collected approximately 24 months before
the baseline [18F]THK5317 PET studies (IQR 14–
34.5 months). Owing to outlying CSF tau values, one patient
with AD dementia was only included in regression analyses
involving CSF ratio measurements.
All patients had originally undergone clinical assessment at
Theme Aging , Karo l inska Univers i ty Hospi ta l ,
Stockholm, Sweden, and underwent follow-up, as detailed
elsewhere [17]. Patients diagnosed with AD dementia fulfilled
the criteria for probable AD and showed in vivo evidence of
Aβ pathology with an abnormal [11C]Pittsburgh compound B
[11C]PIB) scan [19]. Patients diagnosed with prodromal AD
met the criteria for mild cognitive impairment [20] and
showed an abnormal [11C]PIB scan [21]. THK-controls were
recruited through Clinical Trial Consultants AB (Uppsala
University Hospital, Uppsala, Sweden) or from among pa-
tients’ relatives; all were nonsmokers and not taking medica-
tion, completed extensive clinical evaluations, and at inclusion
had no cognitive complaints, prior head injury or known
neurological/psychiatric disorders. Elderly THK-controls
were [11C]PIB-negative, and showed no differences in region-
al [18F]THK5317 binding as compared with young THK-
controls.
Informed consent was obtained from all individual par-
ticipants included in the study. Ethical approval was ob-
tained from the Regional Human Ethics Committee of
Stockholm and the Faculty of Medicine and Radiation
Hazard Ethics Committee of Uppsala University
Hospital, Uppsala, Sweden. A further 15 individuals were
included as CSF biomarker-negative controls (CSF-con-
trols); these were patients with minor cognitive com-
plaints but with basic (cell count, albumin ratio, IgG in-
dex) and core (Aβ1-42/Aβ1-40, P-tau181p, and T-tau) CSF
biomarkers within normal ranges. The CSF samples used
were deidentified leftover aliquots from routine clinical
analyses, following a procedure approved by the Ethics
Committee of the University of Gothenburg (EPN
140811).
CSF measurements
CSF tau was quantified in the Clinical Neurochemistry
Laboratory of the University of Gothenburg, Mölndal,
Sweden, using three approaches: commercially available
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INNOTEST enzyme-linked immunosorbent assay
(ELISA) kits (Fujirebio) for P-tau181P and T-tau, an in-
house ELISA targeting tau species from the N-terminus
to the mid-domain of tau (tau N-Mid), and a single mol-
ecule array (Simoa) method targeting a C-terminally trun-
cated form of tau ending at amino acid 368 (tau-368) [22].
Aβ1-42 and Aβ1-40 were determined using the Meso Scale
Discovery Abe ta Tr ip lex immunoassay (MSD,
Gai thersburg, MD) according to the ki t inser t .
Additional methodological details, including those
pertaining to the validation of the tau N-Mid and tau-
368 assays, are included in Online Resource 1.
PET data acquisition and analysis
Dynamic [18F]THK5317 PET studies were performed
over 60 min following intravenous bolus injection of
217 ± 42 MBq. A static 15 min [18F]FDG scan was per-
formed 30 min after injection of 3 MBq/kg. Baseline and
follow-up images were coregistered to their respective T1-
weighted MR images using PMOD v. 3.5 (PMOD
Technologies., Zurich, Switzerland). In order to account
for possible spillover effects from the white matter, MRI-
based part ia l volume correct ion was applied to
[18F]THK5317 PET images, as implemented in PMOD
[23].
Distribution volume ratio (DVR) images were calculat-
ed for [18F]THK5317 using the cerebellar cortex as the
reference tissue [12, 24]. For [18F]FDG [18], standardized
uptake value ratio (SUVR) was used as the outcome mea-
sure using the pons as the reference region.
Following segmentation of T1 images using SPM8, the
inverse transformation parameters generated were used to
spatially warp a probabilistic atlas into native space in
order to sample the parametric images [25]. Bilateral grey
matter regions of interest (ROIs) were based on previous-
ly published findings with [18F]THK5317 [17], and in-
cluded the frontal, temporal (medial, lateral aspects), pa-
rietal, posterior cingulate and occipital cortices, as well as
an isocortical composite ROI comprising these regions
minus medial temporal structures. Two additional com-
posite regions approximating the Braak staging scheme
for tau pathology [26] were also included: a limbic ROI
(B r a ak I I I / IV ) comp r i s i n g t h e h i ppoc ampu s ,
parahippocampus, amygdala, fusiform and middle inferior
temporal gyri, orbital and straight frontal gyri, parietal-
temporal-occipital junctions and the temporal poles, and
an isocortical ROI (Braak V/VI) comprising all isocortical
regions except the precentral and postcentral gyri. Annual
rates of change in [18F]THK5317 DVR and [18F]FDG
SUVR were calculated as follows: (follow-up value −
baseline value)/between-scan interval (years) [18].
Determination of regional [18F]THK5317 and CSF tau
cut-off values
CSF P-tau181p and T-tau values were classified as abnor-
mal using cut-off values of >80 pg/mL and > 400 pg/mL,
respectively [27]. Unpublished internal cut-off values of
>272 pg/mL and <0.038 were used for tau N-Mid and tau-
368/T-tau, respectively. These were determined using re-
ceiver operating characteristic (ROC) analysis (highest
combined sensit ivi ty and specifici ty) among 50
biomarker-positive AD patients (low Aβ1-42, high P-
tau181p and T-tau) and 50 cognitively unimpaired
biomarker-negative individuals. Regional [18F]THK5317
DVR cut-off values were defined using the mean plus
two standard deviations of the DVR values in the THK-
control group (elderly and young combined), in agree-
ment with previous approaches for both tau [6] and Aβ
PET [28]. Given the lack of cut-off values for tau-368 and
tau-368/tau N-Mid, as well as the absence of controls with
both CSF and [18F]THK5317 data, concordance using
these measures was not investigated.
Statistical analysis
Patient characteristics and CSF measures were compared
using the Mann-Whitney U test. To examine the relation-
ship between regional PET ([18F]THK5317 DVR and
[18F]FDG SUVR) and CSF measures, nonparametric
rank-based estimation multilinear regression models were
implemented [29]. Here, PET measures were regressed
onto CSF values, adjusting for age, ventricular volume
and the time between the CSF and PET investigations.
For models examining CSF tau values in relation to base-
line [18F]THK5317 DVR, isocortical composite [18F]FDG
SUVR, included as an interaction term with CSF tau, was
binarized using a median value of 1.4. Simple slope anal-
yses were used to assess multiple linear regression two-
way interactions [30]. All analyses were performed using
R, v.3.3.2, with significance set at p < 0.05, two-tailed.
ROC-derived areas under the curve (AUC) for CSF tau
measures were compared between AD patients and CSF-
controls using the pROC package, v.1.10 [31].
Results
Demographic, clinical and CSF data are presented in
Table 1. As expected, baseline Mini-Mental State
Examination (MMSE) scores were significantly lower in
AD dementia patients than in prodromal AD patients
(p < 0.01). MMSE scores at follow-up were significantly
lower than scores at baseline, in prodromal AD patients
(p < 0.01), and across prodromal AD and AD dementia
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patients combined (p < 0.01). Tau-368/T-tau ratios were
lower in AD dementia patients than in prodromal AD
patients (p < 0.05).
According to the selection criteria for CSF-controls, the
levels of P-tau181p and T-tau were significantly higher in AD
patients. A clear group separation was also seen when using
novel tau fragments, with AUC values for these close to 1.
There were no significant differences in AUC values between
groups (Online Resources 2, 3 and 4).
Relationship between baseline PET measures and CSF
tau
Regression models for baseline [18F]THK5317 DVR (Fig. 1a,
c; Online Resource 5) showed that tracer retention in the lat-
eral temporal and parietal lobes, as well as in the isocortical
composite and Braak V/VI ROIs, was associated with P-
tau181p levels, while T-tau levels were associated only with
isocortical composite uptake. Tau-368 levels were associated
with [18F]THK5317 DVR in the lateral temporal and frontal
regions, as well as in the isocortical and Braak III/IV ROIs,
and tau-368/tau N-Mid ratios were significantly associated
with [18F]THK5317 DVR in the temporal ROIs, as well as
in the parietal and occipital cortices. In contrast, tau-368/T-tau
ratios were associated with [18F]THK5317 DVR only in the
parietal lobe. Although the direction of these associations was
negative, with the exception of tau ratios, as hypothesized, the
relationship between CSF tau levels and [18F]THK5317 DVR
varied according to the degree of glucose hypometabolism.
Specifically, a significant interaction was observed between
CSF tau measures and isocortical metabolism ([18F]FDG
SUVR) whereby those with higher metabolism (SUVR
>1.4; n = 7, five prodromal AD, two AD dementia) showed
positive slopes for the above-described associations, while
those with more impaired metabolism (SUVR <1.4; n = 6,
four prodromal AD, two AD dementia) showed negative
slopes, similar to the findings observed at the group level (in
analyses using ratios, the additional AD dementia subject had
an SUVR >1.4; Online Resource 6).
A significant association was observed between baseline
parietal [18F]FDG SUVR and P-tau181p levels (Fig. 1b, c;
Online Resource 5). Significant associations were also found
between tau N-Mid levels and [18F]FDG SUVR in the poste-
rior cingulate, as well as in the Braak composite ROIs. Tau
ratios were associated with lateral temporal (tau-368/T-tau)
and isocortical composite (tau-368/tau N-Mid) metabolism.
With respect to the strength of the associations, CSF tau on
average explained 51.6% and 36.2% of the variance in region-
al [18F]THK5317 and [18F]FDG uptake values, respectively
(average R2 0.516 for [18F]THK5317, 0.362 for [18F]FDG;
Online Resource 7). Tau-368 levels showed a stronger asso-
ciation than other CSF tau measures with regional
[18F]THK5317 DVR (average R2 0.443 and 0.651,
respectively; Online Resource 7).
Table 1 Demographic, clinical
and CSF data Prodromal AD AD dementia AD combined
Number of patients
Baseline 7 7 14
Follow-up 6a 4 10
Age at baseline (years) 65 [62, 73.5] 64 [59, 66] 65 [59.3, 74]
Male, n (%) 2 (29) 2 (29) 4 (29)
APOE ε4, n (%) 4 (57) 5 (71) 9 (64)
MMSE score
Baseline 29 [28, 29.5] 23 [23, 24.5]b 25.5 [23.3, 28.8]
Follow-up, median [IQR] 25 [24, 27]c 20 [17, 23.8] 24 [18.5, 25]c
[11C]PIB (composite SUVR) 1.72 [1.68, 1.87] 1.74 [1.68, 1.88] 1.73 [1.67, 1.88]
Aβ1–42 (pg/mL) 236.1 [217, 453] 202.2 [162.4, 310.3] 218 [193, 379]
P-tau181p (pg/mL) 68 [47, 76] 58 [54, 98] 63 [47, 87]
T-tau (pg/mL) 538 [346, 683] 529.1 [455, 815] 534 [372, 755]
Tau N-Mid (pg/mL) 213 [118, 294] 275 [135, 420] 240 [135, 355]
Tau-368 (pg/mL) 12.3 [11, 14.2] 9.57 [8.4, 14.8] 12.1 [9.4, 14.5]
Tau-368/T-tau 0.026 [0.02, 0.032] 0.019 [0.018,0.022]b 0.018 [0.023, 0.026]
Tau-368/tau N-Mid 0.06 [0.053, 0.083] 0.041 [0.035, 0.071] 0.055 [0.040, 0.071]
Data are presented as median [quartile 1, quartile 3] unless otherwise specified
a Two patients had progressed to AD dementia at clinical follow-up
b Significantly lower, relative to prodromal AD (p < 0.01)
c Significantly lower, relative to baseline (p < 0.01)
Eur J Nucl Med Mol Imaging
Relationship between rate of change in PET measures
and CSF tau
Given the smaller number of participants who completed
follow-up PET studies, the interaction term (isocortical
[18F]FDG) used in baseline [18F]THK5317 models was
omitted to avoid overfitting, with rate of change values
simply regressed onto CSF tau values, adjusting for co-
variates. For [18F]THK5317 uptake, P-tau181p levels were
found to be associated with parietal rate of change, while
tau N-Mid levels were associated with rates of change in
parietal and Braak regions (Fig. 2a, c; Online Resource 8).
Tau ratios were associated with the rate of change in
[18F]THK5317 uptake in lateral temporal and isocortical
composite regions, and tau-368/tau N-Mid ratios were al-
so associated with the rate of change in Braak regions.
The rates of change in [18F]FDG SUVR in lateral tempo-
ral and posterior cingulate regions were significantly as-
sociated with tau-368/T-tau ratios (Fig. 2b, c; Online
Resource 8). Similar to the cross-sectional findings, CSF
tau measures showed a stronger association with
[18F]THK5317 uptake than with [18F]FDG uptake
( a v e r a g e R 2 0 . 5 0 1 a n d 0 . 3 9 5 , r e s p e c t i v e l y ;
Online Resource 9).
Concordance between tau biomarkers
Regional [18F]THK5317 DVR cut-off values were as fol-
lows: 1.11 (medial temporal), 1.28 (lateral temporal), 1.38
(parietal), 1.29 (posterior cingulate), 1.44 (frontal), 1.34
(isocortical composite), 1.22 (Braak III/IV), and 1.33
(Braak V/VI). Concordance findings are summarized in
Fig. 3 and Online Resource 10. In all the AD patients
( p o o l e d ) , t h e a v e r a g e c o n c o r d a n c e b e tw e e n
[18F]THK5317 uptake and INNOTEST tau measures
was approximately 50%. Although a similar level of con-
cordance was reached when using tau N-Mid, agreement
was substantially higher when using the tau-368/T-tau
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ratio (79%). When using INNOTEST measures and tau N-
Mid, discordance was primarily in the form of isolated
[18F]THK5317 PET positivity. Only isolated CSF positiv-
ity was found when using tau-368/T-tau. This pattern held
when subgroups were examined separately, although con-
cordance was higher overall in AD dementia patients than
in those with prodromal AD (Online Resources 11 and
12).
Illustrative cases
The following four cases illustrate differing biomarker
profiles. For CSF, concordance with [18F]THK5317 up-
take was based on established tau measures (P-tau181p
and T-tau). Two patients showed concordant positive
profiles while two showed isolated [18F]THK5317 posi-
tivity. When considering all ROIs, no patients showed
isolated CSF positivity. These cases are presented to
highlight various CSF tau profiles in the context of high
cortical tau burden.
Prodromal AD
The PET and CSF biomarker findings in two patients with
prodromal AD are presented in Fig. 4a, c. Both patients
showed high cortical [18F]THK5317 uptake (above cut-
off values in nine ROIs (case 1) and eight of nine ROIs
(case 2) and temporoparietal hypometabolism at baseline.
Using P-tau181p and T-tau, one patient (case 1) was con-
cordant positive with the [18F]THK5317 findings, while
the other (case 2) showed CSF tau concentrations below
the cut-off values. One patient (case 1) showed increased
[18F]THK5317 uptake, mainly in the temporal and parie-
tal regions, with decreased [18F]FDG uptake in the lateral
temporal cortex and the parietal cortex/posterior cingulate.
The other patient (case 2) also showed increased
[18F]THK5317 DVR in the medial parietal region, but
with more widespread changes in metabolism, including
in frontal areas. CSF tau N-Mid levels in the case 1 pa-
tient were nearly double those in the case 2 patient; tau
ratios also showed a similar difference. Tau-368 levels,
however, were similar. At clinical follow-up, the case 1
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patient showed cognitive decline (in terms of MMSE
score) and was diagnosed with AD dementia. In contrast,
the case 2 patient showed relative cognitive stability and
the diagnosis of prodromal AD was unchanged.
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AD dementia
The PET and CSF biomarker findings in two patients with
AD dementia are presented in Fig. 4b, c. In contrast to the
first patient (case 3), who showed concordant positive bio-
markers using INNOTEST tau, the second patient (case 4)
showed a discordant profile, with isolated [18F]THK5317
positivity. At baseline, both patients showed high uptake of
[18F]THK5317 in cortical regions (above regional cut-off
values, except for a borderline DVR value in the posterior
cingulate in the case 4 patient), and low [18F]FDG uptake
in temporal, parietal and frontal regions. [18F]THK5317
uptake was higher at follow-up than at baseline in the fron-
tal and parietal regions in both patients, with additional
involvement of the temporal cortex in the case 3 patient.
Both patients showed metabolic decline, predominantly in
temporal areas. Large differences were seen in tau N-Mid
and tau-368 levels and the tau-368/tau N-Mid ratio; how-
ever, both patients showed similar tau-368/T-tau ratios. No
cognitive decline was seen in the case 3 patient at follow-
up, while a decline in MMSE score of 2 points was seen in
the case 4 patient.
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Fig. 4 Imaging and CSF profiles in patients with a baseline diagnosis of
prodromal AD (a, c), and AD dementia (b, c). Given the widespread use
of P-tau181p and T-tau in the clinical work-up of patients with dementia
disorder, these measures were selected to define concordance (a, b).
[18F]THK5317 positivity was considered present when a high
percentage of ROIs showed DVR values above the defined cut-off
values for THK-controls
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Discussion
In this retrospective longitudinal study, the relationship be-
tween PET and CSF tau biomarkers was found to vary in
relation to the degree of isocortical glucose metabolism.
While a negative association was observed in those with more
globally decreased [18F]FDG uptake, positive slopes, in line
with the findings of previous studies, were found in those with
more preserved glucose metabolism. This interaction with
[18F]FDG uptake was observed for both established and
novel CSF tau fragments. The levels of all forms of CSF tau
investigated were found to be negatively associated with
[18F]FDG SUVR.
Given the unclear relationship between established CSF tau
biomarkers and NFT burden [32, 33], increases in P-tau181p
and T-tau levels may in fact reflect increased tau secretion
resulting from the spread of AD-affected cells at risk of tangle
pathology [34], with increases in tau-368 levels reflecting an
expansion in the pool of C-terminal fragments, possibly due to
increased cleavage activity. In this way, higher levels of these
biomarkers would precede the appearance of NFT pathology
and neurodegenerative changes on [18F]FDG PET. This sce-
nario may explain the positive associations with
[18F]THK5317 uptake at baseline observed in this study and
in previous studies using [18F]flortaucipir [4–7]. The inverse
association between tau biomarker levels seen in patients with
more impairedmetabolism, by contrast, may reflect a decrease
in the release of neuronal tau to the CSF. Indeed, several
studies, including recent work using stable isotope labelling
kinetics (SILK) to monitor the half-life and turnover rate of tau
[35], have shown that, following an initial increase, CSF tau
levels decrease in patients with symptomatic AD [15, 16,
36–38]. This may reflect a deceleration in neurodegenerative
processes and/or a reduction in the number of viable neurons
releasing tau. The inverse association with tau-368 levels may
also reflect a slowing in the production of tau. Another intrigu-
ing hypothesis, however, is that this truncated tau formmay be
sequestered in NFTs and thus represent a more direct tangle
marker than, for example, P-tau181p. Possibly, ratios incorpo-
rating tau-368 (particularly the tau-368/N-Mid ratio) might
better reflect this process, in much the same that way Aβ1–
42/Aβ1–40 better reflects Aβ pathology. The strong associa-
tions between tau-368 levels and baseline [18F]THK5317 up-
take, and between tau-368 ratios and the change in
[18F]THK5317 uptake, lend support to this hypothesis.
Previous studies addressing the relationship between cross-
sectional [18F]FDG uptake and CSF tau levels (P-tau181p and
T-tau) in patients with AD have shown mixed results: al-
though all have shown an inverse association, some have
shown no significant association [39], significant associations
only for P-tau181p [40] and T-tau [41] levels, or significant
associations for both [42]. In our cohort, a significant negative
association was found only between P-tau181p levels and
parietal metabolism at baseline. Interestingly, P-tau181p levels
were also associated with the rate of change in [18F]THK5317
DVR in the parietal lobe, with this pattern (i.e. CSF tau levels
associated with baseline metabolism and the rate of change in
[18F]THK5317 uptake in the same ROI) also observed for the
tau-368/T-tau ratio (lateral temporal), tau-368/tau N-Mid ratio
(isocortical composite) and, most strikingly, tau N-Mid levels
(posterior cingulate and Braak composite regions). Together,
these findings suggest a nonlinear relationship between the
accumulation of AD-type PHF tau and neurodegeneration
[18, 43], similar to that observed for Aβ [44]. Further, our
results suggest that tau N-Mid might prove suitable for cap-
turing increases in tangle pathology and synaptic impairment,
acting as both a state marker (reflecting the intensity of the
disease process) and a stage marker (reflecting the cumulative
extent of the degenerative process) [45].
The level of agreement between dichotomized
[18F]THK5317 uptake and CSF tau levels was somewhat low-
er, overall, than that found in the only other study so far to
have examined concordance between tau biomarkers
([18F]flortaucipir, and P-tau181p and T-tau) [6]. This may relate
to cohort-specific differences (age and CSF tau levels, as well
as MMSE scores were higher and lower, respectively, in the
study by Mattsson et al. [6], which also had a shorter time
between CSF sampling and PET), ROI definition, tracer char-
acteristics, and, possibly, the control subjects used to define
tau PET cut-off levels. Similar to the study by Mattsson et al.
[6], however, we also found higher concordance rates among
AD dementia subjects than in subjects with prodromal AD.
However, using single biomarkers concordance was markedly
improved when using tau-368/T-tau. Although the findings
for tau-368/T-tau and baseline [18F]THK5317 DVR were lim-
ited, this improved concordance, combined with the strong
association between this measure and longitudinal increases
in [18F]THK5317 retention, suggests that the tau-368/T-tau
ratio may better reflect the shift between soluble and insoluble
pools of tau than the single analytes (P-tau181p, T-tau, tau N-
Mid) investigated. This would also probably hold true for tau-
368 alone and as a ratio with tau N-Mid, although we were
unable to directly test this in this study due the lack of a priori
cut-off values or controls with both CSF and [18F]THK5317
PET data available.
With regard to the patterns of discordance, isolated
[18F]THK5317 positivity was the predominant finding for P-
tau181p, T-tau and tau N-Mid. By contrast, only isolated CSF
positivity was found using tau-368/T-tau. Possibly, the isolat-
ed [18F]THK5317 positivity may reflect a deceleration in neu-
rodegeneration and/or the spread of NFT pathology, as previ-
ously described [16, 37]. The pattern of discordance seen with
tau-368/T-tau lends partial support to this idea, in that the
spread of tangle pathology would be accompanied by a de-
crease in soluble C-terminal fragments, a process that would
precede suprathreshold [18F]THK5317 DVR values. With
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regard to the cases presented, however, all four of the patients
showed increases in [18F]THK5317 DVR and decreases in
[18F]FDG SUVR, despite only the patients of cases 2 and 4
showing values below the thresholds for P-tau181p, T-tau and
tau N-Mid. However, both these patients showed low baseline
isocortical glucose metabolism. These observations, com-
bined with our regression findings, suggest that tau bio-
markers may initially follow an offset parallel upward course,
followed by divergence, as CSF tau levels decline. Although
this may indeed reflect the sequestration of tau fragments in
NFTs, given the strong coupling between tangle pathology
and neurodegeneration in AD [46], this decrease in soluble
tau may relate less to a slowing of degenerative processes
and more to a shift in the way tau is released from tangle-
bearing cells [35].
Certain methodological limitations complicate the interpre-
tation of the present findings. Firstly, in addition to the modest
sample size, which precluded comparisons between sub-
groups (prodromal AD, AD dementia), not all participants
completed follow-up PET. Also, due to the limited number
of subjects, and the exploratory nature of this study, we did
not correct for multiple comparisons. Moreover, the AD de-
mentia subgroup represented a limited cross section of disease
severity; with the exception of one AD dementia patient who
had an MMSE score of 17, all had MMSE scores that placed
them in the mildly impaired range. Ideally, Aβ-positive cog-
nitively unimpaired elderly would also have been included so
as to cover the entire AD continuum. In addition, although
recent ev idence indica tes off - ta rge t b inding of
[18F]THK5351 to monoamine oxidase B (MAO-B) [47–49],
it remains unclear how well these findings extrapolate to
[18F]THK5317, given results showing that despite a similar
cortical laminar distribution, the MAO-B-specific tracer
[3H]deprenyl and [3H]THK5117 do not compete at the con-
centration ranges used in PET studies [50]. This, combined
with the low levels of MAO-B in cortical regions [51], sug-
gests that the DVR values reported here largely reflect specific
binding of [18F]THK5317 to PHF-tau. Further, longitudinal
CSF sampling performed concurrently with PET studies
would have allowed a better understanding of the trajectories
of tau biomarkers, in particular whether a decline in CSF tau
levels precedes increases in [18F]THK5317 retention. Lastly,
partial volume correction of longitudinal data would ideally
have been performed usingMRI at follow-up. However, given
the low rates of atrophy reported within isocortical regions
over comparable time intervals [52], this would not be expect-
ed to have had an important effect on our results.
Conclusion
Although our findings are preliminary and subject to the
above-mentioned caveats, they suggest that both positive
and negative associations may exist between CSF and PET
tau biomarkers, and that the directionality of their relationship
may depend on the type of tau form measured, and/or an as-
yet-unclear interplay between tau pathology and neurodegen-
eration. By comparison with P-tau181p and T-tau, the novel
fragments investigated in this study showed greater sensitivity
toward findings with [18F]THK5317 and [18F]FDG PET, and
improved concordance with binarized [18F]THK5317 mea-
surements. CSF and PET tau biomarkers, however, probably
capture different aspects of tau pathology, similar to that pro-
posed for CSFAβ1–42 and amyloid PET [53]. Further studies
incorporating longitudinal CSF analysis and tau PET imaging
in larger cohorts are required to clarify the findings reported
here and to address their potential implications in the context
of the recently proposed dichotomous classification scheme
that seeks to combine tau biomarkers with those for Aβ and
neurodegeneration [54].
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